Business
Novocure to Participate in Upcoming Investor Conferences
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore
About this update from Novocure Limited
[{"type":"text","content":" ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences:\n\n\n\nEvercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables, Florida. William Doyle, Executive Chairman, will take part in a fireside chat at 2:10 p.m. ET.\n\n\n\n\nPiper Sandler Healthcare Conference on Thursday, December 5, 2024, in New York City. Mr. Doyle will take part in a fireside chat at 12:00 p.m. ET.\n\n\n\nLive audio webcasts of each presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.\n\n\nAbout Novocure\n\n\nNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.\n\n\nNovocure’s global headquarters is located in Root, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.\n\n\nForward-Looking Statements\n\n\nIn addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. Yo...